The stock of Bristol-Myers Squibb Co (NYSE:BMY) is a huge mover today! About 52.97 million shares traded hands or 341.78% up from the average. Bristol-Myers Squibb Co (NYSE:BMY) has declined 16.63% since March 7, 2016 and is downtrending. It has underperformed by 24.23% the S&P500.
The move comes after 5 months negative chart setup for the $83.85B company. It was reported on Oct, 10 by Barchart.com. We have $46.85 PT which if reached, will make NYSE:BMY worth $5.03B less.
Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on October, 25. They expect $0.63 earnings per share, up 61.54% or $0.24 from last year’s $0.39 per share. BMY’s profit will be $1.06B for 19.78 P/E if the $0.63 EPS becomes a reality. After $0.69 actual earnings per share reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -8.70% negative EPS growth.
Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage
Out of 15 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 7 “Hold”. This means 33% are positive. Bristol-Myers Squibb Company has been the topic of 33 analyst reports since July 28, 2015 according to StockzIntelligence Inc. On Friday, December 18 the stock rating was initiated by Atlantic Securities with “Underweight”. The firm has “Buy” rating by UBS given on Friday, April 29. Hilliard Lyons initiated the stock with “Neutral” rating in Monday, May 23 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Outperform” rating by Credit Suisse on Monday, May 9. The firm has “Buy” rating by UBS given on Tuesday, September 29. The stock has “Market Perform” rating given by BMO Capital Markets on Monday, January 25. On Friday, September 9 the stock rating was maintained by Barclays Capital with “Equal-Weight”. Berenberg downgraded Bristol-Myers Squibb Co (NYSE:BMY) on Thursday, August 11 to “Hold” rating. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Equal Weight” rating given on Friday, April 29 by Barclays Capital. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Hold” rating given on Thursday, July 14 by Jefferies.
According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.”
Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.01, from 0.93 in 2016Q1. The ratio improved, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Welch And Forbes Limited Company has 286,228 shares for 0.64% of their US portfolio. Inverness Counsel Llc Ny last reported 17,722 shares in the company. Martingale Asset Management Limited Partnership reported 51,741 shares or 0.06% of all its holdings. Chemical Savings Bank last reported 45,673 shares in the company. The Rhode Island-based New England Professional Planning Group has invested 0.27% in Bristol-Myers Squibb Co (NYSE:BMY). Moreover, Jarislowsky Fraser has 0.7% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 1.89 million shares. Community Trust & Invest Co holds 0.03% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 2,785 shares. Waddell And Reed Fincl last reported 8.27 million shares in the company. Eagleclaw Managment Ltd Llc last reported 10,272 shares in the company. Kornitzer Cap Management Inc Ks has 0.08% invested in the company for 62,750 shares. Mu Investments has invested 0.07% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Janney Montgomery Scott reported 956,277 shares or 1.08% of all its holdings. City Co owns 20,378 shares or 0.67% of their US portfolio. Brick And Kyle Assoc last reported 58,433 shares in the company. Pettee Invsts accumulated 4.01% or 56,301 shares.
Insider Transactions: Since May 3, 2016, the stock had 0 insider purchases, and 9 insider sales for $16.83 million net activity. ANDREOTTI LAMBERTO sold $1.67M worth of stock or 23,200 shares. Another trade for 11,820 shares valued at $859,219 was made by Elicker John E on Tuesday, June 14. Another trade for 3,519 shares valued at $255,004 was sold by Caldarella Joseph C. 34,594 shares with value of $2.47M were sold by Caforio Giovanni on Tuesday, May 3. Bancroft Charles A sold $2.14M worth of stock or 30,201 shares. $5.11M worth of shares were sold by LEUNG SANDRA on Friday, May 6.
More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Investorplace.com which released: “3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and …” on October 10, 2016, also Nasdaq.com with their article: “Bristol-Myers Squibb Enters Oversold Territory” published on October 10, 2016, Businesswire.com published: “Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 …” on October 09, 2016. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: Businesswire.com and their article: “New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces …” published on October 03, 2016 as well as Benzinga.com‘s news article titled: “Jim Cramer Shares His Thoughts On Bristol-Myers Squibb Co And Sirius XM …” with publication date: October 08, 2016.
BMY Company Profile
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.